Key Metrics
10.2
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
5 - 10
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
190
H index
H-Index
Journal's h-index reflects the collective citation impact of the authors publishing in the journal. The h-index is defined as the maximum value of h such that the given journal has published at least h papers that have each been cited at least h times.
0.94
5-Year SI
5-year SI
- N/A 2-year SI
- 0.93 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q1
Oncology
SJR
- Q1 Oncology
- Q1 Cancer Research
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
1.21
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
Topics Covered
- Cancer
- Antigen
- Mutant
- Lung cancer
- Extracellular matrix
- Head and neck
- Immunotherapy
- Tyrosine kinase
- Breast cancer
- Camptothecin
- Gemcitabine
- Radiation
- Glioblastoma
- Oxidative stress
- Cell cycle
- Antitumor activity
- DNA damage
- Monoclonal antibody
- Lymphoma
- Homologous recombination
Journal Specifications
| Overview | |
| Publisher | AMER ASSOC CANCER RESEARCH |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2002 |
| Publisher URL | Visit website |
Planning to publish in Molecular Cancer Therapeutics ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Selected Articles from This Issue
- 2 Apr 24
- Molecular Cancer Therapeutics
-
Full paper
Selected Articles from This Issue
- 1 Feb 24
- Molecular Cancer Therapeutics
-
Full paper
Acknowledgment to Reviewers
- 3 Jan 24
- Molecular Cancer Therapeutics
-
Full paper
Selected Articles from This Issue
- 3 Jan 24
- Molecular Cancer Therapeutics
-
Full paper
Selected Articles from This Issue
- 1 Dec 23
- Molecular Cancer Therapeutics
-
Full paper
Selected Articles from This Issue
- 1 Nov 23
- Molecular Cancer Therapeutics
Scite analysis
Powered by scite_
10.9k articles received 253.5k citations see all
- 12,249 Supporting
- 238,673 Mentioning
- 817 Contrasting
Editorial notices
- 16 Retractions
- 0 Withdrawals
- 43 Corrections
- 25 Errata
- 0 Expression of Concern
FAQs
How long has Molecular Cancer Therapeutics been actively publishing?
Molecular Cancer Therapeutics has been in operation since 2002 till date.
What is the publishing frequency of Molecular Cancer Therapeutics ?
Molecular Cancer Therapeutics published with a Monthly frequency.
How many articles did Molecular Cancer Therapeutics publish last years ?
In 2023, Molecular Cancer Therapeutics published 13 articles.
What is the eISSN & pISSN for Molecular Cancer Therapeutics ?
For Molecular Cancer Therapeutics,eISSN is 1538-8514 and pISSN is1535-7163.
What is Citescore for Molecular Cancer Therapeutics ?
Citescore for Molecular Cancer Therapeutics is 10.2.
What is H index for Molecular Cancer Therapeutics ?
H index for Molecular Cancer Therapeutics is 190.
What is SNIP score for Molecular Cancer Therapeutics ?
SNIP score for Molecular Cancer Therapeutics is 1.21.
What is the SJR for Molecular Cancer Therapeutics ?
SJR for Molecular Cancer Therapeutics is Q1.
Who is the publisher of Molecular Cancer Therapeutics ?
AMER ASSOC CANCER RESEARCH is the publisher of Molecular Cancer Therapeutics.